Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 380-390

  Cadete, Virgilio J J ^a   Sawicka, Jolanta ^a   Bekar, Lane K ^a   Sawicki, Grzegorz ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

matrix metalloproteinase; MLC kinase; MLC phosphatase; myosin light chain; phosphorylation

Indexed keywords

1 (5 IODO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; DOXYCYCLINE; GELATINASE A; LACTATE DEHYDROGENASE; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 1; MYOSIN LIGHT CHAIN KINASE; MYOSIN LIGHT CHAIN PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; PHOSPHORYLATION AND DEPHOSPHORYLATION; PHOSPHORYLATION INHIBITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

MATRIX METALLOPROTEINASE; MLC KINASE; MLC PHOSPHATASE; MYOSIN LIGHT CHAIN; PHOSPHORYLATION;

AMIDES; ANIMALS; AZEPINES; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; MYOCARDIAL REPERFUSION INJURY; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN KINASE; NAPHTHALENES; PHOSPHORYLATION; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883250907     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12289     Document Type: Article

References (38)

1. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R, (2010). Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 122: 2039-2047.
2. Arrell DK, Neverova I, Fraser H, Marban E, Van Eyk JE, (2001). Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1. Circ Res 89: 480-487.
3. Arrell DK, Elliott ST, Kane LA, Guo Y, Ko YH, Pedersen PL, et al. (2006). Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways. Circ Res 99: 706-714.
4. Bench TJ, Jeremias A, Brown DL, (2011). Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol Res 64: 561-566.
5. Cadete VJ, Sawicka J, Polewicz D, Doroszko A, Wozniak M, Sawicki G, (2010). Effect of the Rho kinase inhibitor Y-27632 on the proteome of hearts with ischemia-reperfusion injury. Proteomics 10: 4377-4385.
6. Cadete VJ, Sawicka J, Jaswal JS, Lopaschuk GD, Schulz R, Szczesna-Cordary D, et al. (2012). Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. FEBS J 279: 2444-2454.
7. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R, (2000). Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839.
8. Chow AK, Cena J, Schulz R, (2007). Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152: 189-205.
9. Cole WC, Welsh DG, (2011). Role of myosin light chain kinase and myosin light chain phosphatase in the resistance arterial myogenic response to intravascular pressure. Arch Biochem Biophys 510: 160-173.
10. Doroszko A, Polewicz D, Sawicka J, Richardson JS, Cheung PY, Sawicki G, (2009). Cardiac dysfunction in an animal model of neonatal asphyxia is associated with increased degradation of MLC1 by MMP-2. Basic Res Cardiol 104: 669-679.
11. Doroszko A, Polewicz D, Cadete VJ, Sawicka J, Jones M, Szczesna-Cordary D, et al. (2010). Neonatal asphyxia induces the nitration of cardiac myosin light chain 2 that is associated with cardiac systolic dysfunction. Shock 34: 592-600.
12. Fert-Bober J, Basran RS, Sawicka J, Sawicki G, (2008a). Effect of duration of ischemia on myocardial proteome in ischemia/reperfusion injury. Proteomics 8: 2543-2555.
13. Fert-Bober J, Leon H, Sawicka J, Basran RS, Devon RM, Schulz R, et al. (2008b). Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Res Cardiol 103: 431-443.
14. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM, (2004). Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 109: 1196-1205.
15. Gross ER, Gross GJ, (2007). Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs 12: 367-388.
16. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. (2002). S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297: 1186-1190.
17. Kanski J, Behring A, Pelling J, Schoneich C, (2005a). Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am J Physiol Heart Circ Physiol 288: H371-H381.
18. Kanski J, Hong SJ, Schoneich C, (2005b). Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine- containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem 280: 24261-24266.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
20. Lin HB, Cadete VJ, Sawicka J, Wozniak M, Sawicki G, (2012). Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteomics 75: 5386-5395.
21. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. (2009). Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: e21-e181.
22. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
23. Mizuno Y, Isotani E, Huang J, Ding H, Stull JT, Kamm KE, (2008). Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo. Am J Physiol Cell Physiol 295: C358-C364.
24. Moir LM, Ng HY, Poniris MH, Santa T, Burgess JK, Oliver BG, et al. (2011). Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br J Pharmacol 164: 83-92.
25. Nagareddy PR, Rajput PS, Vasudevan H, McClure B, Kumar U, Macleod KM, et al. (2012). Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol 165: 705-715.
26. Okamoto T, Akaike T, Nagano T, Miyajima S, Suga M, Ando M, et al. (1997). Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys 342: 261-274.
27. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H, (2001). Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276: 29596-29602.
28. Omura T, Teragaki M, Takagi M, Tani T, Nishida Y, Yamagishi H, et al. (1995). Myocardial infarct size by serum troponin T and myosin light chain 1 concentration. Jpn Circ J 59: 154-159.
29. Polewicz D, Cadete VJ, Doroszko A, Hunter BE, Sawicka J, Szczesna-Cordary D, et al. (2011). Ischemia induced peroxynitrite dependent modifications of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction. J Cell Mol Med 15: 1136-1147.
30. Ravkilde J, Botker HE, Sogaard P, Selmer J, Rej R, Jorgensen PJ, et al. (1994). Human ventricular myosin light chain isotype 1 as a marker of myocardial injury. Cardiology 84: 135-144.
31. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. (2008). Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-e146.
32. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, et al. (2005). Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112: 544-552.
33. Stull JT, Kamm KE, Vandenboom R, (2011). Myosin light chain kinase and the role of myosin light chain phosphorylation in skeletal muscle. Arch Biochem Biophys 510: 120-128.
34. Sweeney HL, Stull JT, (1986). Phosphorylation of myosin in permeabilized mammalian cardiac and skeletal muscle cells. Am J Physiol 250 (4 Pt 1): C657-C660.
35. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, et al. (2009). Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 77: 826-834.
36. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R, (2002). Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549.
37. Yamada T, Matsumori A, Tamaki S, Sasayama S, (1998). Myosin light chain I grade: a simple marker for the severity and prognosis of patients with acute myocardial infarction. Am Heart J 135 (2 Pt 1): 329-334.
38. Yasmin W, Strynadka KD, Schulz R, (1997). Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 33: 422-432.